InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator ...

One factor that seems to be involved is C5a, a protein involved in chemotaxis. Theoretically, blocking C5a receptor (C5aR) activity could form a therapeutic strategy for RA. The recently developed ...